Radioactive treatment for advanced kidney cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a radioactive medicine (called 161Tb-PSMA) that delivers radiation directly to kidney cancer cells that have a specific marker (PSMA). It is for people whose kidney cancer has spread and has not responded to at least two prior treatments. The goal is to see if this new therapy can help shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of kidney cancer called clear cell renal cell carcinoma that has spread to other parts of the body.
- You must have tried at least two previous treatments, including one that targets blood vessels (like sunitinib or pazopanib) and one immunotherapy (like nivolumab or pembrolizumab), and your cancer must have continued to grow during or after that treatment.
- A special PET scan (called PSMA-PET) must show that most of your cancer spots have a marker called PSMA.
- You need to be generally able to care for yourself (performance status 0 or 1) and have a life expectancy of at least 6 months.
- Your blood, kidney, and liver function must be within certain limits, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This study tests a radioactive drug called Lu-177 PSMA to see if it can help people with advanced kidney cancer that has not responded to other treatments. It aims to slow the cancer's growth and improve quality of life.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
This trial tests a radioactive drug and its imaging partner to find and treat kidney cancer that has spread. You get a scan first to see if the cancer absorbs the drug, and if it does, you receive the therapy.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.